Table 1.

Socio-demographic and clinical characteristics (N=90)

Demographics	Mean±SD	Range
Age (years)	41.8±9.0	22–59
Education (years)	11.6±2.3	6–17
Monthly Income (USD)	417 ± 351	0–1300
	No.	%
Gender: Male	64	71.1
Race:
African American	37	41.1
Caucasian	38	42.2
Native American	2	2.2
Mixed/Other	13	14.4
Ethnicity: Hispanic	5	5.6
Employment: Currently employed/Student	9	10
Marital Status:
Married	6	6.7
Never Married	58	64.4
Other (divorced, widowed)	25	27.8
Diagnosis	No.	%
Schizophrenia	45	50
Schizoaffective Disorder	45	50
Psychiatric Symptom Severity	Mean±SD	Range
GAF	39.6±6.6	30–60
PANSS General Score	32.4±7.1	20–49
PANSS Negative Symptoms	13.5±4.9	7–30
PANSS Positive Symptoms	15.4±5.2	7–31
Calgary Score	5.22±4.0	0–15
Addiction Severity	Mean±SD	Range
Number of cigarettes/week	108.6±98.7	0–510
Number of standard drinks/week	35.3±46.1	0–269
Number of drinking days/month	14.8±8.6	2–30
Cocaine use (days/month)	2.2±4.7	0–20
Marijuana use (days/month)	6.6±10.2	0–30
Sedative use (days/month)	2.5±8.0	0–30
Psychiatric Medications	No. of patients	%
Atypical antipsychotic drugs	82	91.1
Quietapine	35	38.9
Risperidone	33	36.7
Olanzapine	18	20
Aripiprazole	16	17.8
Ziprasidone	8	8.9
Clozapine	4	4.4
Conventional antipsychotic drugs	17	18.9
Fluphenazine decanoate	9	10
Haloperidol decanoate	5	5.5
Haloperidol	3	3.3
Antidepressants	49	54.4
SSRI’s	27	30
Non-SSRI antidepressants	28	31.1
Bupropion	7	7.77
Mood stabilizers	26	28.9
Valproate	19	21.1
Lamotrigine/oxcarbazepine	7	7.77
Topiramate	2	2.2
Lithium	1	1.1
Benzodiazepines/sedatives	27	30
Other medications	20	22.2
Benztropine	19	21.1
Atomoxetin	1	1.1